Register Login

INFLARX N.V. (IFRX)

SymbolIFRX
NameINFLARX N.V.
SectorHEALTH CARE
RegionEurope
IndustryBiotechnology: Pharmaceutical Preparations
AddressWINZERLAER STRASSE 2, JENA, 7745, Germany
Telephone+49 3641508180
Fax—
Email—
Websitehttps://www.inflarx.de
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001708688
Description

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Additional info from NASDAQ:
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

2026-05-14 09:28

New Form SCHEDULE 13G - InflaRx N.V. <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0000908834-26-000234 <b>Size:</b> 53 KB

Read more
2026-05-12 19:03

New Form SCHEDULE 13G - InflaRx N.V. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001193125-26-219985 <b>Size:</b> 122 KB

Read more
2026-05-08 13:03

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

Read more
2026-05-08 12:15

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

Read more
2026-05-07 09:34

New Form 424B5 - InflaRx N.V. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001140361-26-019440 <b>Size:</b> 1 MB

Read more
2026-05-06 17:02

New Form 424B5 - InflaRx N.V. <b>Filed:</b> 2026-05-06 <b>AccNo:</b> 0001140361-26-019288 <b>Size:</b> 1 MB

Read more
2026-05-06 12:33

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

Read more
2026-05-06 12:30

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

Read more
2026-05-06 12:28

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

Read more
2026-05-06 12:25

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

Read more